Antiviral Treatment for Genital Herpes Outbreak
For a genital herpes outbreak, treat with oral acyclovir 400 mg three times daily for 5 days, valacyclovir 500 mg twice daily for 5 days, or famciclovir 125 mg twice daily for 5 days. These three regimens are equally effective for episodic treatment of recurrent genital herpes 1.
Treatment Approach Based on Clinical Scenario
First Clinical Episode (Initial Outbreak)
For patients presenting with their first recognized genital herpes episode, longer treatment duration of 7-10 days is required 1:
- Acyclovir 400 mg orally three times daily for 7-10 days, OR
- Acyclovir 200 mg orally five times daily for 7-10 days, OR
- Valacyclovir 1 g orally twice daily for 7-10 days, OR
- Famciclovir 250 mg orally three times daily for 7-10 days
Treatment should be extended beyond 10 days if healing remains incomplete 1. First episodes are typically more severe with longer viral shedding and healing times compared to recurrent episodes.
Recurrent Episodes (Episodic Treatment)
For patients with established genital herpes experiencing a recurrence, 5-day treatment courses are sufficient 1:
- Acyclovir 400 mg orally three times daily for 5 days, OR
- Acyclovir 200 mg orally five times daily for 5 days, OR
- Acyclovir 800 mg orally twice daily for 5 days, OR
- Famciclovir 125 mg orally twice daily for 5 days, OR
- Valacyclovir 500 mg orally twice daily for 5 days
Critical timing consideration: Treatment must be initiated during the prodrome or within 1 day of lesion onset to achieve meaningful benefit 1. Provide patients with a prescription to keep on hand so they can start treatment immediately when symptoms begin.
Severe Disease Requiring Hospitalization
For patients with complications such as disseminated infection, pneumonitis, hepatitis, or CNS involvement (meningitis/encephalitis), intravenous acyclovir 5-10 mg/kg body weight every 8 hours for 5-7 days or until clinical resolution is required 1.
Special Population Considerations
HIV-Infected Patients
HIV-infected patients require longer treatment courses (5-14 days rather than 5 days) and should NOT receive short-course therapy (1-3 days) 2. These patients experience:
- Slower healing
- More extensive disease
- Higher risk of treatment failure
- Potential for acyclovir-resistant strains
For suppressive therapy in HIV-infected patients, valacyclovir should be dosed at 500 mg twice daily (not once daily) 2.
Pregnant Patients
Acyclovir is the first-line choice during pregnancy due to the most extensive safety data 2, 3. For prophylaxis after 36 weeks gestation in women with a history of genital herpes, use:
- Acyclovir 400 mg three times daily until delivery, OR
- Valacyclovir 500 mg twice daily until delivery 3
Choosing Between Antivirals
While acyclovir, valacyclovir, and famciclovir demonstrate comparable clinical efficacy 1, valacyclovir and famciclovir offer superior convenience with less frequent dosing, which may improve adherence during prolonged treatment 1.
Valacyclovir is the only antiviral FDA-approved for once-daily suppressive therapy and has a 3-day episodic treatment option 4. A 3-day course of valacyclovir 500 mg twice daily is equivalent to 5-day treatment for recurrent episodes 5.
Common Pitfalls to Avoid
- Do not use topical acyclovir - it is substantially less effective than oral therapy and its use is discouraged 6, 1
- Do not use short-course therapy (1-3 days) in HIV-infected patients - they require full 5-14 day courses 2
- Do not delay treatment - efficacy depends on starting within 1 day of symptom onset for recurrent episodes 1
- Avoid valacyclovir 500 mg once daily in patients with very frequent recurrences (≥10 episodes/year) - this dose appears less effective than other regimens 1
Monitoring and Adverse Effects
These antivirals are generally well-tolerated with occasional nausea or headache 2. No laboratory monitoring is needed for episodic or suppressive therapy unless significant renal impairment exists 2. For high-dose IV acyclovir, monitor renal function at initiation and 1-2 times weekly during treatment 2.
Treatment Failure
If lesions do not begin resolving within 7-10 days, suspect acyclovir resistance (particularly in immunocompromised patients). Obtain viral culture with susceptibility testing and treat confirmed resistance with IV foscarnet 2.